Trial · NCT00124982
Results by group952
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 952
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations | ST Abatacept (ABA)-Previous User | Death | 1 | participants | |
| Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations | ST ABA-Current User | Death | 1 | participants | |
| Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations | ST Abatacept (ABA)-Previous User | SAEs | 50 | participants | |
| Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations | ST ABA-Current User | SAEs | 59 | participants | |
| Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations | ST Abatacept (ABA)-Previous User | Related SAEs | 10 | participants | |
| Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations | ST ABA-Current User | Related SAEs | 16 | participants | |
| Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations | ST Abatacept (ABA)-Previous User | SAEs Leading to Discontinuation | 9 | participants | |
| Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations | ST ABA-Current User | SAEs Leading to Discontinuation | 8 | participants | |
| Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations | ST Abatacept (ABA)-Previous User | AEs | 350 | participants | |
| Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations | ST ABA-Current User | AEs | 473 | participants | |
| Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations | ST Abatacept (ABA)-Previous User | Related AEs | 190 | participants | |
| Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations | ST ABA-Current User | Related AEs | 273 | participants | |
| Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations | ST Abatacept (ABA)-Previous User | AEs Leading to Discontinuation | 17 | participants | |
| Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to Discontinuations | ST ABA-Current User | AEs Leading to Discontinuation | 24 | participants | |
| Short-term Period: Number of Participants With AEs of Special Interest | ST Abatacept (ABA)-Previous User | Infections (pre-specified) | 26 | participants | |
| Short-term Period: Number of Participants With AEs of Special Interest | ST ABA-Current User | Infections (pre-specified) | 38 | participants | |
| Short-term Period: Number of Participants With AEs of Special Interest | ST Abatacept (ABA)-Previous User | Serious Infections (pre-specified) | 6 | participants | |
| Short-term Period: Number of Participants With AEs of Special Interest | ST ABA-Current User | Serious Infections (pre-specified) | 7 | participants | |
| Short-term Period: Number of Participants With AEs of Special Interest | ST Abatacept (ABA)-Previous User | Benign, malignant, and unspecified neoplasms | 8 | participants | |
| Short-term Period: Number of Participants With AEs of Special Interest | ST ABA-Current User | Benign, malignant, and unspecified neoplasms | 7 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00124982/results